Efficacy and safety of glecaprevir and pibrentasvir treatment for 8 or 12 weeks in patients with recurrent hepatitis C after liver transplantation: a Japanese multicenter experience

Yoshihide Ueda, Tsuyoshi Kobayashi, Toru Ikegami, Satoshi Miuma, Shugo Mizuno, Nobuhisa Akamatsu, Akinobu Takaki, Masatoshi Ishigami, Mitsuhisa Takatsuki, Yasuhiko Sugawara, Yoshihiko Maehara, Shinji Uemoto, Hiroshi Seno

Research output: Contribution to journalArticlepeer-review

11 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Efficacy and safety of glecaprevir and pibrentasvir treatment for 8 or 12 weeks in patients with recurrent hepatitis C after liver transplantation: a Japanese multicenter experience'. Together they form a unique fingerprint.

Medicine & Life Sciences